期刊
LEUKEMIA & LYMPHOMA
卷 59, 期 6, 页码 1300-1311出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2017.1365859
关键词
Geriatric; dose modification; dose adjustment; dose reduction; toxicity; transplant ineligible
资金
- [P30 CA008748]
- NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER
Multiple myeloma (MM) is a plasma cell neoplasm that affects elderly individuals with two-thirds of patients over 65 years at diagnosis. However, data available are derived from clinical trials conducted in younger patients. Fewer studies investigated treatment options in the elderly. This review summarizes the clinical outcomes and toxicities associated with therapeutic regimens in older patients including doublet, triplet and high dose therapyin newly diagnosed patients and relapsed patients with MM. We highlight the importance of an approach tailored to individuals, incorporates the geriatric frailty assessment, considers comorbiditiess and commits to early recognition and management of toxicities ranging from myelosuppression to polypharmacy. To date, no trial has prospectively investigated a tailored treatment paradigm in older patients based on frailty and/or comorbidities. As the population ages, the proportion of MM patients with advanced age will grow. Studies are indicated to determine optimal treatment approaches in this increasingly heterogeneous geriatric population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据